A narrative review of bone disease in spondyloarthropathy: molecular mechanisms and emerging advances

Spondyloarthropathies (SpA) are chronic inflammatory disorders characterized by the paradoxical coexistence of bone loss and pathological new bone formation, leading to syndesmophytes, ankylosis, erosions, and osteoporosis. These skeletal changes severely impair mobility and heighten fracture risk. This narrative review was conducted by non-systematically searching PubMed, Scopus, Google Scholar, and Web of Science databases up to September 2025 for studies addressing the molecular mechanisms, imaging correlates, and therapeutic strategies in bone disease of SpA. Reference lists were manually screened to include additional relevant literature. Evidence highlights the pathogenic role of cytokines such as tumor necrosis factor (TNF), interleukin (IL)-17, and IL-23 in orchestrating crosstalk between immune and bone cells. Dysregulation of the Wnt/β-catenin pathway and the receptor activator of nuclear factor-κB (RANK)–RANK ligand (RANKL)–osteoprotegerin (OPG) axis underpins the imbalance between osteoclast-mediated resorption and osteoblast-driven ossification. Imaging modalities, including MRI and high-resolution quantitative CT, have advanced early detection and monitoring of structural lesions. Biologic and targeted synthetic agents, notably TNF inhibitors, IL-17 antagonists, and Janus kinase inhibitors, effectively reduce inflammation and bone loss but show limited impact on syndesmophyte progression. Integration of molecular biomarkers, multi-omics profiling, and advanced imaging may enable precision medicine approaches. Therapeutic strategies directly targeting Wnt and BMP signaling represent promising avenues to prevent pathological ossification. Bone disease in SpA arises from intertwined inflammatory, genetic, and mechanical mechanisms. Despite therapeutic advances, structural progression remains unresolved. Future research should focus on interventions that couple anti-inflammatory activity with modulation of bone remodeling to prevent fractures and ankylosis.

Authors

Institutions

Publication Details

Journal
Egyptian Rheumatology and Rehabilitation
Published
2025-12-08
DOI
https://doi.org/10.1186/s43166-025-00363-z
Primary Topic
Spondyloarthritis Studies and Treatments
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

A narrative review of bone disease in spondyloarthropathy: molecular mechanisms and emerging advances

Betty Rachma, Yuliasih Yuliasih, Arinditia Triasti Putri, Lita Diah Rahmawati et al.
Egyptian Rheumatology and Rehabilitation
Spondyloarthritis Studies and Treatments
article

A narrative review of bone disease in spondyloarthropathy: molecular mechanisms and emerging advances

Betty Rachma, Yuliasih Yuliasih, Arinditia Triasti Putri, Lita Diah Rahmawati, Awalia Awalia, Cahyo Wibisono Nugroho
article en

Abstract

Spondyloarthropathies (SpA) are chronic inflammatory disorders characterized by the paradoxical coexistence of bone loss and pathological new bone formation, leading to syndesmophytes, ankylosis, erosions, and osteoporosis. These skeletal changes severely impair mobility and heighten fracture risk. This narrative review was conducted by non-systematically searching PubMed, Scopus, Google Scholar, and Web of Science databases up to September 2025 for studies addressing the molecular mechanisms, imaging correlates, and therapeutic strategies in bone disease of SpA. Reference lists were manually screened to include additional relevant literature. Evidence highlights the pathogenic role of cytokines such as tumor necrosis factor (TNF), interleukin (IL)-17, and IL-23 in orchestrating crosstalk between immune and bone cells. Dysregulation of the Wnt/β-catenin pathway and the receptor activator of nuclear factor-κB (RANK)–RANK ligand (RANKL)–osteoprotegerin (OPG) axis underpins the imbalance between osteoclast-mediated resorption and osteoblast-driven ossification. Imaging modalities, including MRI and high-resolution quantitative CT, have advanced early detection and monitoring of structural lesions. Biologic and targeted synthetic agents, notably TNF inhibitors, IL-17 antagonists, and Janus kinase inhibitors, effectively reduce inflammation and bone loss but show limited impact on syndesmophyte progression. Integration of molecular biomarkers, multi-omics profiling, and advanced imaging may enable precision medicine approaches. Therapeutic strategies directly targeting Wnt and BMP signaling represent promising avenues to prevent pathological ossification. Bone disease in SpA arises from intertwined inflammatory, genetic, and mechanical mechanisms. Despite therapeutic advances, structural progression remains unresolved. Future research should focus on interventions that couple anti-inflammatory activity with modulation of bone remodeling to prevent fractures and ankylosis.

Egyptian Rheumatology and RehabilitationVol. 52(1)
Universitas Airlangga (ID), Universitas Dr. Soetomo (ID)
Openalex Percentile: Top 45%
Spondyloarthritis Studies and Treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.